Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Notch-Pathway Oncology and Fibrosis Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for JAG1 (CD339) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | JAG1 ECD-Fc Fusion Protein (Met1-Ser1046, Human IgG1 Fc). HEK293 expressed for native glycosylation. Sequence verified, >95% purity, Endotoxin <0.01 EU/µg. | View JAG1 Products |
| Gene Delivery | JAG1 Full-Length Lentivirus with CMV promoter, C-terminal GFP/Flag tag. For stable cell line generation preserving native membrane topology for cis/trans signaling studies. | View JAG1 Products |
| Benchmark Ab | Anti-JAG1 Neutralizing Antibody (Clone: 15D1-Rb). Recombinant rabbit monoclonal, sequence verified for DSL domain epitope mapping. | View JAG1 Products |
| Validator | JAG1 siRNA Kit (Set of 3 pre-designed). Validated knockdown efficiency >80% at mRNA level by qPCR. | View JAG1 Products |
| Related Target A | NOTCH1 – Primary receptor mediating JAG1 oncogenic signaling; essential for downstream pathway validation. | View NOTCH1 Products |
| Related Target B | DLL4 – Functionally related Notch ligand; JAG1 upregulation mediates resistance to anti-DLL4 therapies. | View DLL4 Products |
| Related Target C | JAG2 – Critical paralog for selectivity counter-screening; distinguishes JAG1-specific from pan-Jagged inhibitors. | View JAG2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| JAG1/JAG2 Selectivity (paralog cross-reactivity) | Human/Mouse/Cyno JAG1 and JAG2 ECD-Fc proteins with strictly matched N-terminal DSL domain boundaries; >95% purity; confirmed <0.1% cross-reactivity by orthogonal assays. |
| Native Conformation & Glycosylation (Notch binding) | HEK293-expressed antigens preserving native glycosylation patterns critical for Notch1/2 interaction; Endotoxin <0.01 EU/µg prevents TLR4 activation artifacts. |
| Cross-species Cyno/Mouse Toxicology Bridging | Human/Cyno/Mouse JAG1 ortholog proteins with sequence-verified extracellular domains. |
| Lack of Positive Controls | Clinical-grade benchmark antibodies and matched isotype controls included. |
| False Positives / Off-target Signaling | Validated JAG1 siRNA and full-length lentivirus for genetic rescue and specificity checks in reporter assays. |
| Cell-Based Signaling & Internalization (for ADCs) | Lentivirus for stable cell lines preserves transmembrane anchoring and cis-inactivation; GFP tag enables quantification of internalization for ADC development. |
Live JAG1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for JAG1 therapeutics is intensifying, with a strategic pivot from pan-Notch inhibitors (associated with gastrointestinal toxicity) toward ligand-specific approaches. JAG1, historically overlooked in favor of DLL4, is emerging as a critical compensatory mechanism in anti-DLL4 resistance and a direct regulator of cancer stem cells (CSCs) in solid tumors. As first-generation DLL4 inhibitors face efficacy ceilings, the next wave of R&D targets JAG1-specific blockade to disrupt tumor angiogenesis and the CSC niche without disrupting intestinal homeostasis. Key functional domains include the DSL domain and multiple EGF-like repeats (including an atypical EGF-like 2), which are essential for Notch receptor binding and signaling. Mutations in JAG1 are causative for Alagille syndrome (ALGS1), with documented variants (VAR_026296, VAR_026297, VAR_026298) affecting the EGF-like domains. The clinical landscape now features a shift from traditional mAbs to bispecific antibodies, ADCs, and combination therapies, with major players exploring indications in solid tumors (breast, pancreatic, lung) and fibrosis (liver, lung).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Blocking Antibody (mAb) | Emerging Biotechs, Notch-focused biopharma | Solid Tumors (Breast, Pancreatic, Lung), Liver Fibrosis | Binding & Selectivity Assay (Need high-purity JAG1/JAG2 ECD-Fc pair) |
| Bispecific / Decoy Receptor | Immuno-oncology innovators, Preclinical biotech | Immuno-oncology, Stroma-rich tumors | Heterodimer Validation (Need cross-reactive species bridging) |
| ADC | Early-stage programs (CSC targeting) | Triple-Negative Breast Cancer, Lung Adenocarcinoma | Internalization Assay (Requires full-length JAG1 Lentivirus stable cells) |
| Small Molecule / Peptide | Academic consortia, pathway inhibitor developers | Oncology, Fibrosis | Selectivity Assay (Need domain-truncated mutant proteins) |
| Gene / Cell Therapy | Rare disease gene therapy groups | Alagille Syndrome, Liver Disease | Full-length Expression (Need Lentivirus for stable rescue lines) |
| Combination Therapy | Oncology clinical research | Anti-PD-1 Resistant Tumors | Pharmacodynamic Markers (siRNA for target engagement validation) |